Clinseq_AML

This dataset is used in study "Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling". The original study is published on Leukemia (M Wang, J Lindberg, D Klevebring, C Nilsson, A S Mer, M Rantalainen, S Lehmann and H Grönberg. Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling. Leukemia advance online publication 10 March 2017; doi: 10.1038/leu.2017.48).

It includes demographic information, somatic mutations, normalized RNA sequencing counts, and derived prognostic scores of 274 patients diagnosed with acute myeloid leukemia. 

• sex: Sex (M = male, F = female)
• age:     Age at diagnosis
• aml_etiology:  de novo = AML without any any antecedent causative disease or treatment, s-AML = AML following and antecedent hematological disorder such as MDS, MPN or aplastic anemia, t-AML = AML following radiation or cytotoxic drugs (patients treated with cytotoxic therapy for MDS/MPN are considered s-AML)
• OS: overall survival (days)
• status: Vital status (0 = alive, 1 = deceased)
• cytogenetic risk: cytogenetic risk classification
• ELN: the European LeukemiaNet (ELN) risk classification
• FLT3_ITD, DNMT3A, IDH1, IDH2_140, TET2, TP53, RUNX1, NRAS, CEBPA, WT1, KIT, ASXL1, PHF6, KRAS, PTEN, EZH2, PTPN11, U2AF1, SRSF2, SF3B1, STAG2, SMC1A, SMC3, RAD21, NPM1, IDH2_172, FLT3_HS, CEBPA2: somatic mutation (0 = wild type, 1 = mutated)
• ENSG***********: normalized RNA sequencing counts. Details about bioinformatics processing were described in Supplementary Methods of the publication.
• Derived prognostic scores: Details were described in the publication.